AstraZeneca Korea Appoints Ohad Goldberg as New CEO
AstraZeneca Korea announced on April 1 that it has appointed Ohad Goldberg, currently CEO of AstraZeneca Israel, as the new CEO of AstraZeneca Korea, effective May 1.
Goldberg brings over 20 years of international leadership experience in the fields of life sciences, biotechnology, and agricultural technology (Ag-Tech), with proven expertise in commercial operations, market access, and external affairs. He has served in senior global and regional leadership roles, including as global launch leader for respiratory biologics, head of market access and head of the respiratory business in Israel, and as leader of commercial strategy for the European region.
Previously, as CEO of AstraZeneca Israel, Goldberg was recognized for spearheading external partnerships with government, healthcare stakeholders, academia, and innovation platforms. He has also represented the company in various leadership capacities, including as Chairman of the Board of AION Labs and as a board member of Pharma Israel, the association of multinational pharmaceutical companies in Israel.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Goldberg stated, "It is truly an honor to take on this role at a pivotal moment for healthcare reform in Korea. I look forward to working with AstraZeneca Korea’s talented team to contribute to the advancement of healthcare policy and to create sustainable, long-term value for Korean patients and society by expanding equitable access to innovative medicines."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.